Search Results - "Kreačić, M."

Randomised study of high-dose epirubicin versus high-dose epirubicin-cisplatin chemotherapy for advanced soft tissue sarcoma by JELIC, S, KOVCIN, V, MILANOVIC, N, BABOVIC, N, KREACIC, M, RISTOVIC, Z, VLAJIC, M, FILIPOVIC-LJESKOVIC, I

“…A randomised study was started in chemotherapy-naive patients with advanced soft tissue sarcomas who received either epirubicin 60 mg/m 2/24 h (total dose for…”
Get full text

PO-072: Compliance and acute toxicity of chemoradiotherapy for undifferentiated nasopharyngeal cancer by Jovanovic Korda, N, Ursulovic, T, Vucicevic, S, Vujanac, V, Kreacic, M

Get full text

Use of high-dose cytarabine to enhance cisplatin cytotoxicity—effects on the response and overall survival rates of advanced head and neck cancer patients by JELIC, S, STAMATOVIC, Lj, VUCICEVIC, S, PETROVIC, Z, KREACIC, M, BABOVIC, N, JOVANOVIC, N, MIKIC, A, GAVRILOVIC, D

“…It has been reported that cytarabine, acting by at least two different mechanisms, enhances the cytotoxic effect of cisplatin in in vitro systems. The aim of…”
Get full text

PD-044: Weekly Versus Three Weekly Cisplatin in Postoperative Chemoradiotherapy for High Risk Head and Neck Cancer by Jovanovic Korda, N, Vucicevic, V, Svetislav Jelic, J, Miroslav Kreacic, M

Get full text

Randomized study of zorubicin versus zorubicin-cisplatin in undifferentiated carcinoma of the nasopharynx (UCNT) by Jelić, S., Kovčin, V., Milanović, N., Kreačić, M., Pendjer, I., Jovanović, V., Ristović, Z., Oprić, M., Mitrović, L.

“…Background The most active chemotherapy regimens in UCNT were those combining anthracyclines (doxorubicin or epirubicin) and cisplatin. Our previous pilot…”
Get full text

Postoperative chemoradiotherapy for high risk head and neck cancer by Korda, N. Jovanovic, Vucicevic, S, Jelic, S, Kreacic, M

Get full text

P72 Comorbidity and survival in elderly with locoregionally advanced squamocellular head and neck carcinomas (LA SCCHN) by Kreacic, M, Jelic, S, Ursulovic, T, Jovanovic, J, Medic-Milijic, N

Get full text

P.22 Colorectal cancer screening barriers in the elderly by Mladen, D.M, Dragoslav, M.P, Erceg, P, Despotovic, N, Svorcan, P, Kreacic, M

Get full text

8570 Body mass index (BMI) – simple tool for prediction and prognosis in patients with locoregionally advanced head and neck carcinomas (LA HNSCC) by Kreacic, M, Jelic, S, Ursulovic, T, Medic-Milijic, N, Jovanovic, J

Get full text

Dose-finding study of capecitabine in combination with weekly paclitaxel for patients with anthracycline-pretreated metastatic breast cancer by Susnjar, S, Bosnjak, S, Radulovic, S, Stevanovic, J, Gajic-Dobrosavljevic, M, Kreacic, M

“…Capecitabine and paclitaxel show high efficacy, non-overlapping toxicity profiles and preclinical synergism, providing the rationale for their combination in…”
Get more information

5551 POSTER Impact of Cisplatin potentiation by Cytarabine in the 5-FU-CDDP regimen for dismal-prognosis head and neck cancer (HNC) patients; a meta-analysis of 3 local trials involving 492 patients by Jelic, S, Kreacic, M, Ursulovic, T, Vucicevic, S, Gavrilovic, D, Jovanovic, N, Babovic, N, Petrovic, Z, Mikic, A

Get full text

The principles of chemotherapy of colorectal cancer in elderly by Milosevic, D P, Kreacic, M, Despotovic, N, Erceg, P, Milanovic, P, Mihajlovic, G, Mitic, S, Davidovic, M

“…The prevalence of colorectal cancer (CRC) increases significantly with age, with 40% of patients in Europe being older than 74 years of age at the time of…”
Get more information

Vinblastin-carboplatin for metastatic cutaneous melanoma as first-line chemotherapy and in dacarbazine failures: a single-center study by Jelić, S, Babović, N, Stamatović, L, Kreacić, M, Matković, S, Popov, I

“…First-line treatments of metastatic melanoma are usually decarbazine (DTIC) and/or alpha-interferon based, with response rates in the range of at most 20-30%…”
Get full text

Prognostic factors in advanced soft tissue sarcomas (STS) treated with high doses of epirubicin and cisplatin by Milanović, N., Jelić, S., Tomašević, Z., Babović, N., Kreačić, M., Stamatović, Lj

Get full text

Cardioprotection with ICRF-187 (Cardioxane) in patients with advanced breast cancer having cardiac risk factors for doxorubicin cardiotoxicity, treated with the FDC regimen by Jelić, S, Radulović, S, Nesković-Konstantinović, Z, Kreacić, M, Ristović, Z, Bosnjak, S, Milanović, N, Vuletić, L

“…A study of cardioprotection with ICRF-187 (Cardioxane, Eurocetus) has been performed in 35 patients with metastatic breast cancer treated with the FDC regimen…”
Get full text

Epirubicin 150 mg/m2-cisplatin versus epirubicin 180 mg/m2-cisplatin for advanced soft tissue sarcoma by Jelić, S, Babović, N, Kreacić, M, Matković, S, Milanović, N, Gavrilović, D, Tomasević, Z

“…We have previously reported the superiority of the epirubicin 180 mg/m2-cisplatin combination over single drug epirubicin 180 mg/m2 for advanced soft tissue…”
Get more information

Weekly paclitaxel (TAX) and capecitabine (CAP) for metastatic breast cancer (MBC) patients (PTS) previously treated with anthracycline-containing therapy: A phase I dose-finding study by Susnjar, S., Bosnjak, S., Radulovic, S., Stevanovic, J., Gajic-Dobrosavljevic, M., Kreacic, M.

“…Abstract only…”
Get full text

Analyses of the results in the treatment of locally advanced hypopharyngeal carcinoma with different therapeutic approach by Mikić, A, Pendjer, I, Dudvarski, Z, Trivić, A, Hirurgiju, M

“…treatment of locoregional advanced hypopharyngeal cancers of grades III and IV would be surgery and/or radiotherapy. An increasing number of authors has…”
Get full text

A pilot study of high-dose zorubicin in advanced stages of soft tissue sarcoma in adults by Jelić, S, Tomasević, Z, Kreacić, M, Kovcin, V, Radosavljević, D, Vlajić, M

“…High-dose anthracyclines, doxorubicin 75 mg/m2 and epirubicin 150-180 mg/m2, are the most active drugs in the treatment of advanced soft tissue sarcoma. These…”
Get more information

Systemic therapy in carcinoma of the renal parenchyma by Babović, N, Popov, I, Kreacić, M, Jelić, S

Get more information